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Abstract: The 5’-methylthioadenosine phosphorylase (MTAP) gene is located in the chromosomal
region 9p21. MTAP deletion is a frequent event in a wide variety of human cancers; however,
its biological role in tumorigenesis remains unclear. The purpose of this study was to characterize the
MTAP expression profile in a series of gliomas and to associate it with patients’ clinicopathological
features. Moreover, we sought to evaluate, through glioma gene-edited cell lines, the biological impact
of MTAP in gliomas. MTAP expression was evaluated in 507 glioma patients by immunohistochemistry
(IHC), and the expression levels were associated with patients’ clinicopathological features.
Furthermore, an in silico study was undertaken using genomic databases totalizing 350 samples.
In glioma cell lines, MTAP was edited, and following MTAP overexpression and knockout (KO),
a transcriptome analysis was performed by NanoString Pan-Cancer Pathways panel. Moreover,
MTAP’s role in glioma cell proliferation, migration, and invasion was evaluated. Homozygous
deletion of 9p21 locus was associated with a reduction of MTAP mRNA expression in the TCGA
(The Cancer Genome Atlas) - glioblastoma dataset (p < 0.01). In addition, the loss of MTAP expression
was markedly high in high-grade gliomas (46.6% of cases) determined by IHC and Western blotting
(40% of evaluated cell lines). Reduced MTAP expression was associated with a better prognostic in the
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adult glioblastoma dataset (p < 0.001). Nine genes associated with five pathways were differentially
expressed in MTAP-knockout (KO) cells, with six upregulated and three downregulated in MTAP.
Analysis of cell proliferation, migration, and invasion did not show any significant differences between
MTAP gene-edited and control cells. Our results integrating data from patients as well as in silico
and in vitro models provide evidence towards the lack of strong biological importance of MTAP in
gliomas. Despite the frequent loss of MTAP, it seems not to have a clinical impact in survival and
does not act as a canonic tumor suppressor gene in gliomas.
Keywords: glioma; glioblastoma; 5’-methylthioadenosine phosphorylase (MTAP); immunohistochemistry;
tumor biology; proliferation; migration; invasion
1. Introduction
Gliomas represent the most common group of primary central nervous system (CNS) tumors [1].
According to the World Health Organization (WHO), these tumors can be categorized in low-grade
gliomas (LGG, WHO grades I and II) and high-grade gliomas (HGG, WHO grades III and IV) according
to their histological and molecular features [2,3]. Pilocytic astrocytoma (PA) (WHO grade I) is
a good-prognosis childhood tumor, and conversely, glioblastoma (GBM) (WHO grade IV) occurs
mainly in adults and has the poorest prognosis [2,4]. GBM has a mean survival of ~14 months after
gold-standard therapy—surgery—followed by radiation therapy plus concomitant temozolomide [5–7].
GBM accounts for 70% of gliomas and can be subdivided in GBM IDH-wild type (the most frequent,
>90%), previously known as primary (de novo) GBM and exhibiting a short clinical history, and
GBM IDH-mutant, also called secondary GBM, which results from the malignant progression from
lower-grade gliomas of diffuse (WHO grade II) or anaplastic (WHO grade III) astrocytomas [6,8] and is
related to point mutations in IDH1/2 genes.
In fact, several efforts have been made to improve the molecular characterization of GBM. In 2014,
the International Society of Neuropathology recommended the support of molecular analysis for
determining brain tumor entities [9] and, in 2016, the World Health Organization proposed the use of
molecular features, including IDH mutation to GBM, in addition to histologic features in the tumor
entities [3]. Additionally, there are many other biomarkers studied in GBMs as subjects of special
attention. TERT promoter mutations have been found to be markedly high in primary GBMs (from
54% to 83% of the cases) [10]. Further studies have shown poorer survival of TERT-mutated patients
in comparison to TERT-wild type [11–13]. Finally, studies have found an interaction between TERT
promoter mutation and MGMT methylation. By performing pairwise comparisons, it was identified
that MGMT methylation improved the survival of TERT promoter mutated-patients [14]. On the other
hand, TERT-mutant and MGMT unmethylated patients presented the poorest prognosis, pointing
to a possible impact in the use of IDH, TERT, and MGMT in the improvement of diffuse gliomas
classification and prognostication [15].
We previously described the most frequent chromosomal alterations in a series of Brazilian
astrocytomas [11]. We identified chromosome 7 gain, EGFR amplification, and losses in chromosomes
9p, 10, and 13, in accordance with other populations [4,11,16]. We also found 9p- deletion in
approximately 50% of GBMs, affecting primarily the 9p21 locus where several tumor suppressor genes
are located, including CDKN2A/B and MTAP [11].
MTAP (5′-methyltioadenosine phosphorylase) encodes a key enzyme involved in the metabolism
of polyamines and purines [17–19]. This enzyme converts 5′-methyltioadenosine (MTA), a by-product of
polyamine biosynthesis, into adenine and MTR-1-P (methylthioribose-1-phosphate), which are recycled
into AMP (adenosine monophosphate) and methionine [19,20]. This protein is expressed virtually in
all tissues throughout the body, and its homozygous deletion is frequently associated with solid and
hematologic tumors such as mesothelioma, lung carcinoma, hepatocellular carcinoma, gastrointestinal
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stromal tumors, metastatic melanoma, leukemias, and lymphoma [18,21–25]. Therefore, MTAP has
been reported as a tumor suppressor gene [24,26–30]; however, many studies have demonstrated
the contradictory function of MTAP. For instance, the loss of MTAP expression has been associated
with inhibition of growth and progression of head and neck carcinoma and lung cancer by MTA
accumulation [31,32]. Bistulfi et al. [33] showed that knockdown of MTAP blocks prostate cancer
growth in vitro and in vivo. In addition, methionine deprivation acts by inhibiting cell migration,
invasion, and metastasis in breast cancer [34]. Metabolic changes in tumors, especially those relating to
polyamines metabolism, demonstrate that many mechanisms underlying MTAP function need to still
be clarified [35,36]. In gliomas, loss of MTAP locus is also frequently reported [37–41]. Nevertheless,
the clinical and the biological impacts of MTAP are poorly explored in gliomas [37,38,42].
Therefore, the aim of this study was to characterize the MTAP protein expression profile in a large
series of glioma and to associate it with the patients’ clinicopathological features. Moreover, by using
glioma cell lines, the biological role of MTAP was evaluated. By integrating data from patients and
in vitro models, this study showed that, despite the frequent loss of MTAP, it does not have a clinical
impact in survival and does not act as a canonic tumor suppressor gene in gliomas.
2. Materials and Methods
2.1. Cell Lines and Gene Editing
One cell line derived from normal astrocytes (NHA), seven short-term primary glioma cell lines,
and 11 established glioma cell lines were evaluated. The MTAP positive U251 cell line was transfected
with MTAP Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) (MTAP-CRISPR/Cas9 KO) or empty vector CRISPR/Cas9 Plasmid (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), leading to a U251 MTAP−/− clone. The MTAP negative SW1088
cell line was transduced with the MTAP human lentivirus or the blank control lentiviral vector in
accordance with the manufacturer’s instructions (ABM Inc.®, Richmond, BC, Canada), resulting in
SW1088 MTAP+/+ clones. Detailed information about the cell lines used and the gene editing are
described in the Appendix A material.
2.2. Patients
Adult and pediatric glioma tissues were obtained from 507 patients who underwent surgery for
glioma at Barretos Cancer Hospital (BCH), Hospital of Clinics of Faculty of Medicine of São Paulo
University (HCRP), AC Camargo Cancer Center, and The Institute of Cancer Research between 1980
and 2013. Histologic review of the slides was performed by expert neuropathologists (according to
the latest WHO histopathological criteria) [3] to confirm the diagnosis. Overall, patient age ranged
from 0.3 to 82.8 years (median: 57 years old). The stratification showed 49 (9.7%) patients in pediatric
(0–19 years) and 458 (90.3%) in the adult group (>19 years). Histological subtypes of gliomas were
distributed into diffuse astrocytoma (n = 18), anaplastic astrocytoma (n = 24), pediatric glioblastoma
(n = 42), and adult glioblastoma (n = 423). This study was approved by the Ethics Committee of
Barretos Cancer Hospital under approval number 630/2012, number 1175879 (961/2015), and AC
Camargo Cancer Center (number 1485/10).
2.3. DNA Isolation
Tissue from a patient’s tumor was manually microdissected from 4 µm unstained histological
sections. DNA was isolated from each target using the DNeasy Blood and Tissue kit (Qiagen, Valencia,
CA, USA) according to the protocols provided by the supplier. The 260/280 and the 260/230 ratios were
determined by a NanoDrop 2000C spectrophotometer (Thermo Scientific, Wilmington, DE, USA), and
the DNA was quantified using Quant-iT PicoGreen dsDNA (Invitrogen, Eugene, OR, USA) according
to the supplier’s protocol.
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2.4. RNA Extraction and RT-qPCR
RNA from cultured cell lines was isolated using a modified TRIzol® reagent protocol (Thermo
Scientific, Waltham, MA, USA) [43]. In brief, cultured cells were washed twice with Dulbecco’s
phosphate-buffered saline (DPBS; Thermo Scientific, Waltham, MA, USA), and 1.5 mL TRIzol® was
added. Flasks were scraped, and TRizol/cell mixture was transferred to a 1.5 mL eppendorf tube.
Subsequently, 200 µL of chloroform was added, homogenized for 30 s, and centrifuged at 17,982× g
for 15 min. The supernatant was collected, and 750 µL isopropanol was added and kept overnight at
−20 ◦C. Samples were then centrifuged at 17,982× g for 10 min at 4 ◦C. The resulting RNA pellet was
washed twice with 75% ethanol after removing the supernatant. Finally, the RNA pellet was dried and
dissolved in 20 µL of ultra-pure water. The integrity of all the RNA preparations was checked by RNA
600 nano assay (Agilent Technologies, Santa Clara, CA, USA), and RNA concentrations were measured
with NanoDrop™ 2000C spectrophotometer (Thermo Scientific, Waltham, MA, USA). Complementary
DNA (cDNA) was synthesized using Superscript III reverse transcriptase (Thermo Scientific, Waltham,
MA, USA) according to the supplier protocol.
RT-qPCR reactions were carried out in a total volume of 10 µL using 2X Fast SYBR®Green Master
Mix kit (Thermo Scientific, Waltham, MA, USA) containing 100 ng (1 µL) of cDNA, 10 µM (0.8 µL) of
each primer, and 7.4µL of ultra-pure water in a final volume of 20µL. Gene amplification was performed
with the programmable cyclic reactor StepOne ™ Real-Time PCR System (Applied Biosystems, Grand
Island, USA) as follows: 95 ◦C for 10 min; 40 cycles at 95 ◦C for 15 s; and 64 ◦C for 1 min. The primers
used for RT-qPCR amplification of MTAP were forward primer: 5′- TCTTGTGCCAGAGGAGTGTG-3′;
reverse primer: 5′-ACCATTGTCCCCTTTGAGTG-3′. Samples were then normalized using the
housekeeping gene HPRT1 (forward primer: 5′-GACCAGTCAACAGGGGACAT-3′; reverse primer:
5′-CTGCATTGTTTTGCCAGTGT-3′). The normalized expressions of the gene of interest were
calculated using the 2-∆Ct method. The primers used were synthesized by Sigma-Aldrich, St. Louis,
MO, USA, and all reactions were performed in three biological replicates.
2.5. IDH1 Mutation Analysis
The analysis of hotspot mutations of isocitrate dehydrogenase 1 (IDH1-exon 4) was performed
by PCR followed by direct sequencing. Briefly, the IDH1 region of interest was amplified
by PCR using the following primers: 59-CGGTCTTCAGAGAAGCCATT-39 (forward) and
59-CACATTATTGCCAACATGAC-39 (reverse) [11]. An amplification PCR reaction was performed
in a total volume of 15 µL comprising: 1 µL of DNA, 1X buffer solution, 2 mM MgCl2, 200 µM of
each dNTP, 0.3 µM of each primer set, and 0.5 U of Taq DNA polymerase (Invitrogen, Eugene, OR,
USA), and was performed in a Veriti 96-well Thermal Cycler with an initial denaturation at 95 ◦C
for 10 min, amplification for 40 cycles with denaturation at 95 ◦C for 45 s, annealing at 58 ◦C for 45 s,
extension at 72 ◦C for 45 s, and a final extension at 72 ◦C for 10 min. Amplification of PCR products
was confirmed by gel electrophoresis. PCR sequencing was performed using the Big Dye terminator
v3.1 cycle sequencing ready reaction kit (Applied Biosystems, Grand Island, NY, USA) and an ABI
PRISM 3500 xL Genetic Analyzer (Applied Biosystems, Grand Island, NY, USA).
2.6. TERT Mutation Analysis
The analysis of hotspot mutations in the promoter region of the telomerase reverse
transcriptase gene (TERT) was performed by PCR followed by direct Sanger sequencing [44].
Briefly, the TERT promoter region was amplified by PCR using the following primers:
59-AGTGGATTCGCGGGCACAGA-39 (forward) and 59-CAGCGCTGCCTGAAACTC-39 (reverse),
leading to a 235 bp PCR product containing C228T and C250T mutations. Amplification by PCR was
performed with an initial denaturation at 95 ◦C for 15 min, followed by 40 cycles of denaturation at
95 ◦C for 30 s, annealing at 64 ◦C for 90 s, elongation at 72 ◦C for 30 s, and final elongation at 72 ◦C for
7 min. Amplification of PCR products was confirmed by gel electrophoresis. PCR sequencing was
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performed using the Big Dye terminator v3.1 cycle sequencing ready reaction kit (Applied Biosystems,
Grand Island, NY, USA) and an ABI PRISM 3500 xL Genetic Analyzer (Applied Biosystems, Grand
Island, NY, USA).
2.7. MGMT Promoter Methylation
To evaluate the methylation status of the promoter region of the O6-methylguanine-DNA
methyltransferase gene (MGMT), sodium bisulfite treatment of DNA (300–1500 ng) was performed
using the Epitect Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions.
Methylation-specific (MS) PCR for the MGMT promoter was performed as described previously [45].
2.8. Western Blotting Analysis
The Western blot analysis was performed as previously described [42]. In brief, cells were lysed
with lysis buffer (50 mM Tris; pH 7.6; 150 mM NaCl; 5 mM EDTA; 1 mM Na3VO4; 10 mM NaF; 10 mM
sodium pyrophosphate; 1% NP-40) containing protease inhibitor cocktail (0.01 M EDTA; 1 mM DTT; 1
mM Leupeptin; 1 mM PMSF; and 1 µM Aprotinin). The cell lysate was placed on ice for 60 min and
centrifuged at 17,982× g for 15 min. The total protein was quantified using the Bradford method (Quick
Start TM Bradford Protein Assay; Bio-Rad, Hercules, CA, USA). Total proteins were separated by 12%
polyacrylamide gel and transferred onto Trans-Blot Turbo Midi Nitrocellulose Transfer Packs (Bio-Rad,
Hercules, CA, USA). The membrane was incubated with primary followed by secondary antibodies
after blocking with 5% non-fat milk. Immunodetection was performed using the ECL KIT (Amersham
Biosciences, Uppsala, Uppland, Sweden) in ImageQuant LAS 4000 mini (GE Healthcare Life Sciences,
Pittsburgh, PA, USA) and quantified by the platform for scientific image analysis ImageJ (NIH) [46].
The following antibodies were used: polyclonal anti-MTAP antibody (Proteintech, Rosemont, IL,
USA) diluted 1:800 and anti-β actin antibody (Cell Signaling Technology, Danvers, MA, USA) diluted
at 1:2000.
2.9. Immunohistochemistry Analysis
For the immunohistochemistry (IHC) analysis, a tissue microarray (TMA) was constructed with
tumors areas obtained from each case and inserted in the recipient paraffin block using the tissue
arrayer MTA-1 platform (Beecher InstrumentsTM, Silver Springs, MD, USA). To represent possible
heterogeneity of tumors, two 1.0 mm cores from each case were used in TMA blocks. IHC was
performed from 4.0 µm sections of the TMA block for MTAP, as previously described [42]. Glass slides
were deparaffinized and subjected to antigen retrieval in a Pascal pressure chamber (Dako, Carpinteria,
CA, USA). The primary MTAP polyclonal antibody (Proteintech, Rosemont, IL, USA) was diluted 1:300
with the background-reducing medium and kept at 4 ◦C overnight. The Avidin–Biotin Complex (ABC)
method was performed according to the manufacturer‘s recommendations with staining with DAB (3,3’
Diaminobenzidine) and counterstaining with Harris’ hematoxylin (Leica Biosystems, Newcastle, UK).
The extension of immunoreactions was measured according to the following criteria: 0 = negative;
1 = ≤25% of positive cells; 2 = 25–50% of positive cells; 3 =≥50% of positive cells. Moreover, the intensity
of reaction was defined as: 0= negative; 1 = weak; 2= moderate; 3 = strong. Cases presenting the sum
of the scores (extension and intensity) between 0 and 3 were considered negative, and those presenting
scores between 4 and 6 were considered positive. Non-neoplastic tissue microarray (BN 961-Biomax
INC, Rockville, MD, USA) was used as a positive control for IHC reactions.
2.10. In Silico Analysis
MTAP copy number alterations (CNA) data were downloaded from comparative genomic
hybridization/single-nucleotide polymorphism (CGH_SNP) arrays (n = 350) [47]. Based on normalized
MTAP values, patients were stratified in normal (n = 150) (>−0.1) and MTAP homozygous deletion
carriers (n = 200) (≤−1.5). For expression analysis, MTAP mRNA G450 array data were downloaded
(n = 299) [47]. The median MTAP value was calculated considering all samples. Patients with MTAP
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values at least 20% higher than the median were considered positive (n = 138), while those with MTAP
values at least 20% lower than the median were considered negative (n = 161). Finally, for methylation
analysis, MTAP methylation beta values were downloaded from 283 samples [47]. Patients were
stratified as hypermethylated (beta > 0.5) and hypomethylated (beta ≤ 0.5). Integrated in silico analyses
of MTAP CNA expression and methylation status were performed using the TCGA2STAT package
implemented in R software downloaded from https://www.r-project.org/. Moreover, in silico analysis
was conducted to evaluate MTAP expression in glioblastoma subtypes in The Cancer Genome Atlas
(TCGA) dataset. The median MTAP value was calculated considering all samples.
2.11. mRNA NanoStringTM Data Analysis
Gene expression analysis on MTAP gene-edited U251 and SW1088 cell lines was performed
using the NanoString nCounter PanCancer Pathways panel (730 gene transcripts distributed in 13
biological pathways) according to the manufacturer’s standards (NanoString Technologies, Seattle,
WA, USA). Moreover, 24 of 730 genes associated with tumor aggressiveness were selected, and the
differential expression was evaluated to better understand the function of MTAP gene-edited on
migration and invasion ability. Briefly, 100 ng aliquots of RNA were hybridized with probe pools,
hybridization buffer, and TagSet reagents in a total volume of 30 µL and incubated at 65 ◦C for 20 h.
After codeset hybridization overnight, the samples were washed and immobilized to a cartridge using
the Nanostring nCounter Prep Station (NanoString Technologies, Seattle, WA, USA) for 4 h. Finally,
the cartridges containing immobilized and aligned reporter complexes were scanned in the nCounter
Digital Analyzer (NanoString Technologies, Seattle, WA, USA), and image data were subsequently
generated using the high-resolution setting, which takes 577 images per sample. Quality control
assessment of raw NanoString gene expression counts was performed with nSolver Analysis Software
version 2.5 and the default settings (NanoString Technologies, Seattle, WA, USA). Normalization with
internal positive controls and housekeeping genes was performed in R statistical environment using
NanostringNorm package [48]. Normalized log2 mRNA expression values were used for subsequent
data analysis. Genes with fold change (FC) ±2 and p < 0.05 were considered significant.
2.12. xCELLigence Proliferation Assay
U251 MTAP−/− and SW1088 MTAP+/+ cell proliferation was monitored with a real-time cell
analyzer using xCELLigence Technology (Roche Applied Science, Indianapolis, IN, USA). This
impedance value was measured by the Real Time Cell Analysis Dual purpose (RTCA DP) system and
is reported in the dimensionless unit of cell index. Prior to seeding of cells in the 96-well E-plate, 100 µL
Dulbecco’s modified Eagle’s medium (DMEM) was added to wells, and background was recorded.
U251 MTAP−/−; U251 EV; U251 WT and SW1088 MTAP+/+; SW1088 LB; SW1088 WT were split, and
5–10 × 103 cells in 100 µL of media supplemented with fetal bovine serum (FBS; 10%) were added to
each well. Real-time monitoring of cell proliferation measured as cell index was recorded every 5 min
for up to 72 h. Data represent changes in cell index over time.
2.13. Transwell Migration Assay
Boyden chamber type Transwell permeable supports (Corning, Chelmsford St. Lowell, MA, USA)
were used to examine the ability of cells to invade the 8 µm pore size membrane (1 × 105 pores/cm2)
and migrate through the polyethylene terephthalate (PET)-membrane surface. The CRISPR-edited cell
line (U251 MTAP−/−) and the stable expression cell line (SW1088 MTAP+/+) beside the control cell
lines were seeded into the inner chamber at 5 × 104 and 10 × 104, respectively, in 500 µL of DMEM
without serum and allowed to migrate onto the coated undersurface at 37 ◦C in a CO2 incubator
for 24 h. At the bottom, 750 µL of DMEM supplemented with 10% FBS was added to the chambers.
Migrated cells were fixed and stained with hematoxylin and eosin for three minutes followed by
phosphate-buffered saline (PBS) washing of the membranes. The migrated cells in each well were
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counted in ten different fields per experiment under the microscope. The mean values were obtained
from three replicate experiments and were subjected to t-test.
2.14. Cell Invasion Assay
U251 MTAP−/− and SW1088 MTAP+/+ beside control cells were cultured to near confluence
in DMEM+10% FBS. Cells were harvested by trypsinization and washed and suspended in DMEM
without serum at 2 × 105 and 4 × 105 cells/mL. Prior to preparing the cell suspension, the dried layer of
matrigel matrix was rehydrated with serum-free DMEM for 1 h at 37 ◦C. The rehydration solution was
carefully removed, 750 µL DMEM containing 10% FBS was added to each well as a chemoattractant,
and 500 µL (1–2 × 105 cells) of cell suspension was added into the inner chamber Corning, Chelmsford
St. Lowell, MA, USA). The plates were incubated for 24 h at 37 ◦C. The invasive cells on the bottom
surface of the membrane were fixed and stained with hematoxylin and eosin for three minutes followed
by 1X PBS washing of the membranes. The migrated cells in each well were counted in ten different
fields per experiment under the microscope. The mean values were obtained from three replicate
experiments and were subjected to t-test.
2.15. Statistical Analysis
The statistical analysis was performed using SPSS version 24 for Windows TM (IBM, Chicago, Ill,
USA) considering statistically significant values of p < 0.05. Levene and Kolmogorov–Smirnov tests
were performed to test the variance and the normality of the data. One-way ANOVA or Kruskal–Wallis
tests were performed to compare copy number, expression, and methylation of MTAP profiles. ANOVA
followed by Tukey post hoc test was performed to evaluate MTAP expression in glioblastoma subtypes.
The association between clinicopathological categorical variables and MTAP was analyzed by Pearson’s
chi-square test or Fisher exact test. The overall survival (OS) analysis was done by constructing
Kaplan–Meier curves, and the log-rank test was applied for the comparison between the obtained
curves. OS was defined as the time between the date of diagnosis and the date of the patient’s last
information or death. Cell line experiments were analyzed with Student’s t-test and are expressed as
mean values of at least three independent experiments ± standard errors. Differences were considered
significant at * p < 0.05, ** p < 0.01, and *** p < 0.001.
3. Results
3.1. Loss of MTAP Expression is Associated with 9p21 Locus Deletion in Gliomas
Initially, in order to understand the molecular mechanism underlying MTAP expression,
we investigated the impact of copy number alteration (CNA) of 9p21 locus on MTAP mRNA expression
levels in a TCGA-GBM dataset (n = 350). As shown in Figure 1A, MTAP gene expression was
significantly (p < 0.01) lower in the homozygously deleted group (n = 169) than in those with normal
ploidy (n = 181). Since MTAP regulation can also occur by epigenetic mechanisms [27], we then
evaluated the association of MTAP mRNA expression and the methylation status in 283 samples from
the TCGA-GBM dataset (Figure 1B). MTAP gene promoter was methylated in 60 of 283 (21.2%) samples.
However, no association of methylation status and MTAP expression levels in glioblastomas was
observed (Figure 1B, p = 0.633). Additionally, we evaluated the MTAP expression levels in the five
molecular subtypes of TCGA-GBM (n = 291) (Table 1). We found loss of MTAP expression greater than
50% in almost all subtypes analyzed, except for the glioma CpG island methylator phenotype (G-CIMP)
(Table 1). The classical subtype presented a higher frequency of loss of MTAP gene expression with
65.2% (43/66) against only 7.4% (2/25) for the G-CIMP+ subtype (p < 0.001) (Table 1).
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Next, in a set of eleven established and seven short-term primary gliomas cells, we compared 
MTAP copy number with MTAP mRNA and protein expression by RT-qPCR and Western blot, 
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deleted samples compared to matched normal samples (p-value < 0.01). (B) Box-plot of MTAP
expression and promoter methylation in TGCA-GBM dataset. ns: not significant p-value.
Table 1. MTAP differential expression in subtypes of glioblastoma.
Subtype MTAP Positive MTAP Negative Total p-Value
Classical 23 (34.8%) 43 (65.2%) 66 (100%) <0.001
Mesenchymal 36 (41.9%) 50 (58.1%) 86 (100%)
Neural 19 (37.3%) 32 (62.7%) 51 (100%)
Proneural 30 (49.2%) 31 (50.8%) 61 (100%)
G-CIMP+ 25 (92.6%) 2 (7.4%) 27 (100%)
G-CIMP+: glioma-CpG island methylator phenotype.
Next, in a set of eleven established and seven short-term primary gliomas cells, we compared
MTAP copy number with MTAP mRNA and protein expression by RT-qPCR and Western blot,
respectively (Supplementary Table S1). Overall, we found loss of MTAP mRNA expression in 33.3%
(6/18) of the cell lines evaluated (Figure 2), particularly in 36.3% (4/11) of established cell lines, with 25%
(1/4) for pediatric and 42.8% (3/7) for adult glioma cell lines (Figure 2A), and 29% (2/7) of patient-derived
glioma cell lines (Figure 2B). A 100% concordance was found between protein and mRNA levels
(Figure 2C–F). Of note, 40% (6/15) of high-grade glioma (HGG; WHO grade III–IV) cell lines presented
loss of MTAP expression, contrasting with 0% in low-grade glioma (LGG; WHO grade I–II) cell lines
(0/3) (Figure 2A,B). Considering only the GBM subtype, a lack of MTAP mRNA and protein expression
was found in 33.3% (4/12) of samples, with 44.4% (4/9) of adult GBM cell lines having no detectable
MTAP in the cell extracts (Figure 2C,D). These results suggest that MTAP loss of expression is associated
with higher-grade gliomas.
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Figure 2. Loss of MTAP expression is more present in high-grade glioma (HGG) cell lines. MTAP
protein expression analysis of established (A) and short-term primary glioma cells (B) assessed by
Western blotting. Plot representative of MTAP protein (C,D) and gene (E,F) expression in glioma cell
lines. Samples were normalized to HPRT-1 (mRNA) and beta-actin (ACTB) (protein) as an endogenous
control. Abbreviations: CTRL+: positive control.
3.2. MTAP Expression Profile and Clinicopathological As ociation in Glio as
We further valu ted MTAP protein xpr ssion by immunohist chemistry in a large set of diffuse
glioma (n = 507) (Table 2 nd Figure 3). Overall, we found loss of MTAP ex r i i 45.95%
(233/507) of cases, this being observed in 27.8% (5/18) of diffuse astrocytoma, 50.0% (12/24) of anaplastic
astrocytoma, 45.6% (193/423) of adult glioblastoma, and 54.8% (23/42) of pediatric glioblastoma
(Figure 3A–E). When we stratified the samples by grade, the loss of MTAP expression in the high-grade
glioma subgroup was almost two-fold greater (46.6%, 228/489) than in the low-grade glioma subgroup
(27.8%; 5/18) (Table 2 and Figure 3E). However, we did not observe a significant association between
MTAP expression and other patients’ clinicopathological features, such as gender, age, or Karnofsky
Performance Status (KPS), except for tumor location (p = 0.013) (Table 2).
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Table 2. Clinicopathological features of glioma patients and association with MTAP expression.
MTAP Expression
Total (%) Negative (%) Positive (%) p-Value
Gender (N = 491)
Male 300 (61.1) 141 (47.0) 159 (53.0) 0.503
Female 191 (38.9) 83 (43.5) 108 (56.5)
Age group (N = 504)
0–19 49 (9.7) 26 (53.1) 23 (46.9) 0.479
20–59 256 (50.8) 112 (43.8) 144 (56.2)
>59 199 (39.5) 92 (46.2) 107 (53.8)
Location (N = 210)
Frontal Lobe 88 (41.9) 24 (27.3) 64 (72.7) 0.013
Parietal Lobe 41 (19.5) 9 (22.0) 32 (78.0)
Temporal Lobe 66 (31.4) 28 (42.4) 38 (57.6)
Occipital Lobe 10 (4.8) 5 (50.0) 5 (50.0)
Cerebellum 5 (2.4) 4 (80.0) 1 (20.0)
KPS (N = 168)
<70 75 (44.6) 11 (14.7) 64 (85.3) 0.539
>70 93 (55.4) 18 (19.4) 75 (80.6)
Grade (N = 507)
Low Grade 18 (3.6) 5 (27.8) 13 (72.2) 0.149
High Grade 489 (96.4) 228 (46.6) 261 (53.4)
Histologic Subtype (N = 507)
DA (WHO Grade II, NOS) 18 (3.6) 5 (27.8) 13 (72.2) 0.272
AA (WHO Grade III, NOS) 24 (4.7) 12 (50.0) 12 (50.0)
Ped. GBM (WHO Grade IV, NOS) 42 (8.3) 23 (54.8) 19 (45.2)
Ad. GBM (WHO Grade IV, NOS) 423 (83.4) 193 (45.6) 230 (54.4)
GBM status mutation (N = 460)
IDH1 mutation (N = 229)
No 220 (96.1) 117 (53.2) 103 (46.8) 0.185
Yes 9 (3.9) 7 (77.8) 2 (22.2)
TERT promoter mutation (N = 45)
No 11 (24.4) 3 (27.3) 8 (72.7) 0.687
Yes 34 (75.6) 7 (20.6) 27 (79.4)
MGMT promoter methylation (N = 186)
No 120 (64.5) 75 (62.5) 45 (37.5) 0.753
Yes 66 (35.5) 39 (59.1) 27 (40.9)
Abbreviation: DA: diffuse astrocytoma, AA: anaplastic astrocytoma, Ped. GBM: pediatric glioblastoma, Ad. GBM:
adult glioblastoma KPS: Karnofsky Performance Status, NOS: not otherwise specified. T-test (p < 0.05).
Following the assessment of TERT, IDH1 mutational profile, and MGMT methylation status in a
subset of cases, the association of these molecular alterations with the loss of MTAP protein expression
was evaluated. No significant association was observed (Table 2).
Importantly, we evaluated the impact of MTAP expression on overall survival (OS) of patients
diagnosed with GBMs. In total, 398 adult patients were included in the OS analysis from which 83.1%
(n = 331) died during total observation time: 76.6% (n = 138) in the MTAP-negative group and 88.5%
(n = 193) in the MTAP-positive group (Figure 4A). We found that, in adult glioblastoma, patients
exhibiting a lack of MTAP expression had better survival than those presenting MTAP expression
(median survival of 9.8±0.86 vs. 6.23±0.70 months, respectively, p = 0.00023 in log-rank test) (Figure 4A).
Two-year OS rates were 10.6% for the MTAP-negative group and 7.6% for the MTAP-positive group.
In the pediatric context, 40 pediatric glioblastoma patients included in the analysis—86.3% (n = 19)
in the MTAP-negative group and 77.7% (n = 14) in the MTAP-positive group—died during the total
observational time (Figure 4B). There was no association of MTAP loss and patients’ OS, with a median
OS of 13.0±1.71 months in the MTAP-negative group and 14.0±4.83 months for the MTAP-positive
Cells 2020, 9, 492 11 of 24
group (p = 0.499 in log-rank test) (Figure 4B). The two-year OS rates were 7.2% and 5.56% for
MTAP-negative and MTAP-positive groups, respectively.
In order to extend these findings, we performed in silico survival analysis considering CNA status
in TCGA-GBM datasets (n = 246). The analysis did not demonstrate a significant difference between
MTAP CNA and overall survival (Figure 4C; p = 0.942). We further evaluated disease-free survival
(DFS) considering relapse and death as endpoints. Similarly, the five-year DFS was not different
between MTAP groups (Figure 4D; p = 0.230).Cells 2020, 9, 492 11 of 27 
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Figure 3. Immunohistochemistry staining for MTAP in human brain tumor tissues. The human brain
tissue slide used for this study contained 507 cases of patients with different grades of gliomas in
duplicates. Representative images from (A) normal cerebellum tissue (positive control); (400×) (B)
diffuse astrocytoma (grade II); (400×) (C) anaplastic astrocytoma (grade III); 400× (D) glioblastoma
(grade IV); 400×. Arrows indicate vessels with endothelial staining for TAP protein (positive
internal control). (E) Frequency of loss of MTAP protein expression in the glioma dataset according to
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3.3. MTAP Cell Line Editing and Differential Gene Expression
To further underpin the MTAP biological role in gliomas, the U251 cell line, which expressed MTAP,
was transfected with MTAP CRISPR/Cas9 KO to create the stable knockout clones (U251MTAP−/−).
On the other hand, SW1088 cells that normally do not express MTAP were transduced by the MTAP
human lentivirus to establish MTAP xp ession clones (SW1088MTAP+/+). Stable cell lines were
confirmed by Western blotting post puromycin selection (Supplementary Figure S1).
After MTAP gene editing, the transcriptomic profiles of U251MTAP−/− and SW1088MTAP+/+
cells as well as control cells (U251EV and SW1088LB) and parental cells (U251WT and SW1088WT) were
evaluated for the expression of specific genes using the NanoString PanCancer Pathways Panel, which
assessed thirteen canonical pathways (Notch, Wnt, Hedgehog, chromatin modification, transcriptional
regulation, DNA damage control, transforming growth factor-beta (TGF-beta), mitogen-activated
protein kinase (MAP ), he Janus kinase/signal tra sducers and activators of transcri tion (JAK/STAT),
Phosphoinositide 3-ki ase (PI3K), RAS, cell cycle, and apoptosis). In the U251 cell , we found that
the U251MTAP−/− clone showed 17 differentially expressed genes in comparison with controls, with
seven (ANGPT1, NGFR, FN1, COL11A1, SPP1, RASGRF1, and MAPK10) being associated with the
PI3K/RAS/MAPK pathways, three (TGFBR2, THBS1, and BMP5) with the TGF-β pathway, two (IDH2
and ERBB2) belonging to the Driver pathway, and five genes (TNFSF10, SFRP1, PLAT, NOTCH1, and
BRIP1) associated with other pathways (Figure 5A, Supplementary Table S2). When analyzing only
differentially expressed genes (p. adjusted <0.05; log2FC≥±2), we found six upregulated (ANGPT1,
FN1, NGFR, RASGRF1, THBS1, and TNFSF10) and three downregulated genes (BMP5, COL11A1, and
MAPK10) in the MTAP KO cells (Figure 5B).
We further performed the same approach in the SW1088 gene-edited cells. In the SW1088MTAP+/+
clone, we observed significant alterations in six genes (IL6R, GPC4, IL13RA2, MAP2K6, E2F5, and
ETV1) belonging to JAK-STAT, PI3K, WNT, MAPK, transcriptional regulation, and apoptosis pathways
(Figure 5C, Supplementary Table S3). Following adjustment (p-adjusted <0.05; Log2FC>≥2), only
GPC4 and IL13RA2 were differentially expressed when compared with control cells (Figure 5D,
Supplementary Table S3). Subsequently, an analysis of the functional connections among the proteins
encoded by the 17 and the six genes differently expressed by U251MTAP−/− and SW1088MTAP+/+
was performed using STRING software. For U251MTAP−/− cell, 11 of 17 genes had at least two
connections, as shown in Figure 5E. Notably, these 11 genes were centered on five genes (NOTCH1,
ANGPT1, ERBB2, THBS1, and FN1). On the other hand, for SW1088MTAP+/+, only IL6R and MAP2K6
showed the signal connection (Figure 5F).
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Figure 5. Detection of differentially expressed genes aff cted by MTAP gene-edited in glioma cell
lines. (A) Heatmap representing the expression profile of the most differentially expressed genes for
U251MTAP−/− cell compared to U251EV and U251WT cells. (B) Bar plots showing gene expression as
the mean SD of log changes of U251MTAP−/− relative to U251EV and U251WT cell . (C) Heatmap
representing the expression profile of the most differentially expressed genes for SW1088MTAP+/+
cell compared to SW1088LB and SW1088WT cells. (D) Bar plots showing the gene expression as the
mean SD of log changes of SW1088MTAP+/+ relative to SW1088LB and SW1088WT cells. (E,F) Isolated
networks of protein−protein interaction using STRING (http://www.string-db.org). The weight of these
lines represents the confidence within which a predicted interaction occurs. Interactions networks for
17 and six proteins differentially regulated in U251MTAP−/− and SW1088MTAP+/+ cells compared to
controls U251EV and SW1088LB, respectively. Rows represent genes and columns represent cell lines.
Red pixels: upregulated genes; blue pixels: downregulated genes. The intensity of each color denotes
the standardized ratio between each value and the average expression of each gene across all samples.
Each sphere represents an individual protein, and edges represent protein–protein associations. A red
line indicates the presence of fusion evidence; a green line indicates neighborhood evidence; a blue
line indicates co-occurrence evidence; a purple line indicates experimental evidence; a yellow line
indicates text-mining evidence; a light blue line indicates database evidence; and a black line indicates
co-expression evidence. Asterisks (*) labeling the bar indicates a significant difference (p-value < 0.05
and log2FC≥±2) between the gene expression of respective groups and the control. The network nodes
represent proteins. Edges represent protein–protein associations. Student t-test: * p < 0.05, ** p < 0.01,
*** p < 0.001, ns: not significant
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3.4. MTAP Deletion Does Not Modulate Glioma Cell Proliferation
To address the functional impact on cell proliferation, U251MTAP−/−, U251EV, and U251WT
(1x105 cells) as well as SW1088MTAP+/+, SW1088LB, and SW1088WT (5 × 103 cells) were seeded in
E-plates, and then the cell index and the doubling time were evaluated (Figure 6). We observed that
U251MTAP−/− showed analogous kinetic trace characteristics when compared to U251EV after 72 h
(Figure 6A). When we analyzed the cell doubling time, within 24 h (cell doubling time 2.36 ± 1.51
vs. 3.32 ± 0.88; p = 0.400) and persisting up to 72 h (cell doubling time; 10.36 ± 1.64 vs. 11.64 ± 1.40,
p = 0.800), the U251MTAP−/− cell showed increased proliferation rates in relation to U251EV, although
it did not show a significant difference (Figure 6B, 24 h: p > 0.999; 48 h: p > 0.999; 72 h: p = 0.547).
Likewise, the SW1088MTAP+/+ cells did not exhibit distinct proliferation rates (Figure 6C, p > 0.05)
and doubling time (Figure 6D, 24 h: p = 0.700; 48 h: p = 0.885; 72 h: p = 0.885) when compared with the
control clone (SW1088LB). Together, these results suggest that the MTAP gene alone does not modulate
cell proliferation.
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Figure 6. Dynamic monitoring of cell proliferation using impedance technology. Cell index values
representative for U251MTAP−/− vs. U251EV (A) and SW1088MTAP+/+ vs. SW1088LB (C) measured
by the Real Time Cell Analysis (RTCA) assay for 90 h. Plot representative of cell index and doubling
time at 24, 48, and 72 h for U251MTAP−/− vs. U251EV (B) and SW1088MTAP+/+ vs. SW1088LB (D).
Plot representative of three independent experiments. Student t-test: * p < 0.05, ** p < 0.01, *** p < 0.001,
ns: not significant.
3.5. Loss of MTAP Gene is Not Associated with Cell Migration and Invasion
To investigate whether the loss of MTAP could affect glioma cell motility and invasiveness, we
used the transwell cell migration assay (Figure 7A,B). U251MTAP−/− cells promoted decreased ability
of migration compared with U251EV by 10% (U251MTAP−/− 552.5 ± 205.3 vs. U251EV: 614.2 ± 223)
(Figure 7A, p > 0.999), while the overexpressed clone SW1088MTAP+/+ showed an increase in migration
ability about of 19% (SW1088LB: 557.8±40.8 vs. SW1088MTAP+/+: 687.6 ± 138.1) (Figure 7B, p = 0.400).
Regarding the invasive properties of edited cells, as shown in Figure 7C, U251EV cells (601.7 ± 201.6)
exhibited an 8% greater invasion compared to U251MTAP−/− (553.5 ± 92.1), yet it was not statistically
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significant (p = 0.857). Likewise, an increase of SW1088MTAP+/+ invasion was observed in ~12%
(SW1088MTAP+/+: 264.3 ± 50.7 vs. SW1088LB: 230.7 ± 31.9) compared to SW1088LB cell, also not
statistically significant (Figure 7D, p = 0.628). Moreover, we obtained similar results when comparing
U251MTAP−/− and SW1088MTAP+/+ with U251WT and SW1088WT parental controls, respectively
(data not shown).
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Figure 7. MTAP gene does not modulate migration and invasion abilities. Migration potential in
both clone cell lines U251MTAP−/− (A) and SW1088MTAP+/+ (B) compared to controls (U251EV and
SW1088LB) measured by Transwell assays and expressed as relative cell population. Transmembrane
invasion assay of U251MTAP−/− (C) and SW1088MTAP+/+ (D) compared to controls (U251EV and
SW1088LB). Quantification of migrated and invaded cells numbers per field. A minimum of 10 fields
of two separate wells within each experiment were analyzed. The graphs represent data from three
separate experiments. Student t-test: * p < 0.05, ** p < 0.01, *** p < 0.001, ns: not significant.
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Next, to support in vitro results, we evaluated the differential expression of 24 genes associated
with invasion and migration processes. Only two of these genes were differently expressed in the
U251 MTAP gene-edited cell line compared to U251EV cells (Supplementary Figure S2A). The FN1
gene was found to be upregulated (log2FC = 2.26; p = 0.0006) and, inversely, MAPK10 was found
downregulated (log2FC = −3.28; p < 0.0001) in U251MTAP−/− compared to U251EV (Supplementary
Figure S2C). Furthermore, no differential expression was found between SW1088MTAP+/+ and control
(Supplementary Figure S2C).
4. Discussion
In the present study, we evaluated MTAP expression in a large series of gliomas. Moreover, by
using a genome edition gain- or loss-of MTAP-function approach in glioma cell lines, we explored
MTAP biological impact on gliomas. We observed that, despite the frequent loss of MTAP expression in
high-grade gliomas, MTAP was not associated with a worse outcome, and the in vitro models showed
that MTAP does not affect cell line proliferation, invasion, and migration.
Initially, using an in silico approach, we showed that 48% (168/350) of gliomas had 9p21 locus
deleted, and this deletion was directly associated with reduced MTAP expression. In fact, Zhao and
Zhao in a tumor suppressor pan-cancer study reported the association between copy number loss
(9p21) and reduced MTAP mRNA expression [49]. In addition, the homozygous deletion of 9p21
locus was identified to be significantly associated with a decrease of MTAP (mRNA and protein)
expression levels [50]. This region of the human genome is especially interesting because MTAP is
located close to a fragile site [51]. The deletion of this region usually causes co-deletion of MTAP and
some classic and well-known tumor suppressor genes such as CDKN2A/B [52]. The cyclin-dependent
kinase inhibitor 2A (CDKN2A) and the cyclin-dependent kinase inhibitor 2B (CDKN2B) genes both
encode putative regulators of cyclin-dependent kinases on chromosome 9p21 that could lead to
uncontrolled cell proliferation and have been associated with poor prognosis in many cancer types
included gliomas [23,53–55]. The 9p21 chromosomal region deletion is rare in grade I but frequent
in grade IV glioma [39]. Our findings, in combination with the detection of other biomarkers, show
CDKN2A/B could be used to predict 9p21 deletion and to stratify patients for stricter surveillance.
By analyzing the TCGA-GBM dataset, we also observed that deletion, rather than MTAP promoter
methylation, is associated with MTAP mRNA expression. Our results contrast with a recent study that
found a significant association of MTAP methylation with gene expression [40]. However, Hansen
et al. observed a very low coefficient of determination (R2) (0.19) with a low correlation coefficient
(R) value (0.44) clearly below the values considered as strong correlation (>0.6); therefore, caution
should be taken in interpreting the reported correlation between DNA promoter methylation and
MTAP expression described [40].
We then evaluated MTAP expression profile in accordance with the molecular subtype of
glioblastomas described by Verhaak et al. [56] and Noushmehr et al. [16]. When using the TCGA-GBM
dataset, we observed that MTAP loss of expression was more pronounced within the classical subtype
(65.2%), corroborating previous reports that patients with classical subtype are characterized by
CDKN2A gene deletion that is contiguous with the MTAP gene [26]. On the other hand, only 7.4% of
the G-CIMP glioblastomas showed loss of MTAP, which is associated with secondary glioblastoma,
tumor-harboring mutation of the IDH1 gene, and lesions that progressed from LGG [16,57,58].
In glioma cell lines, we observed loss of MTAP in high-grade glioma cells, contrasting with
low-grade glioma (40% vs. 0%). Interestingly, there was no loss of MTAP expression in pediatric GBM
cell lines, whereas 50% (4/8) of adult GBM cell lines presented the loss of expression. These findings
are in line with the less frequent (10–19%) 9p21 locus deletion event in pediatric HGG cases [8,59].
We further characterized MTAP expression by IHC, and we sought to associate it with its prognostic
value. We previously reported that MTAP loss occurs in less than 15% of pilocytic astrocytomas
(WHO grade I) [42]. Herein, we extended the immunohistochemistry analysis to a large set of diffuse
infiltrative astrocytomas and observed association between loss of MTAP expression and malignancy
Cells 2020, 9, 492 17 of 24
grade of gliomas. This result is in line with the report by Suzuki et al. [60] that identified the high
frequency of MTAP deletion (60%) in glioblastoma series but rare presence in low-grade glioma [39,42].
Differently, in glioma cell lines, the loss of MTAP for pediatric glioblastoma (54.8%) was higher than in
adult glioblastoma (45.6%) series. This finding was unexpected and may suggest that our series of
pediatric GBM harbored histological characteristics such as those described in the receptor tyrosine
kinases (RTK) II classic subgroup. These tumors exhibit features of copy number alterations of adult
glioblastomas [8,61]. In a recent study, Frazão et al. [39] identified, in a series of pediatric gliomas, rare
episodes of deletion in grade I glioma (12.2%) but frequent 9p21 deletion in high-grade glioma (62.5%).
These results point to the correlation of MTAP deficiency with increased malignancy and histological
subtype of gliomas [11,38,42,50,60].
Despite the frequent loss of expression associated with higher-grade lesions, when evaluating
its clinical impact in our HGG and adult GBM cases, the loss of MTAP was surprisingly correlated
with a better prognosis. One hypothesis that may explain this fact is that patients diagnosed with
the classical subtype (frequent chromosome 9p deletion) presented better survival after intensive
therapy (chemotherapy/radiotherapy) [56]. Our dataset is composed of patients with primary GBM
characteristics (median age of 59 years, IDH1-mutated in 3.9%) with 79% (287/363) having undergone
chemo or radiotherapy treatment, corroborating this result. In addition, through the bioinformatics
approach, we did not observe any association of MTAP expression/deletion with overall survival
(p = 0.942) and disease-free survival (p = 0.230) from the TCGA-GBM dataset. These results are not in
accordance with Hansen et al. [40], which also analyzed the TCGA-GBM dataset and reported that
MTAP-deleted cases presented worse disease-free survival (DFS) when compared to MTAP-normal
patients. The lack of accuracy of DFS in GBM prognostic evolution, particularly outside a clinical
trial assessment, is already known; therefore, overall survival (OS) is the most used criterion. When
analyzing the same TCGA GBM dataset, we observed that MTAP-deleted patients did not show a
worse OS when compared with MTAP-normal patients. Additionally, in agreement with Hansen et
al. [40], we performed the DFS analysis of the same GBM dataset, considering the gold standard DFS
endpoints (7), namely relapse and death events, different to the study by Hansen that only considered
relapse and censured the events of death. The results also showed a lack of association between MTAP
deletion and GBM patients’ prognosis.
Our NanoString Pan-Cancer Panel analysis of MTAP gene-edited cell lines showed a significantly
altered expression of genes associated with RAS/MAPK/PI3K-AKT and apoptosis pathways after
MTAP gene knockout. Signaling by these pathways governs fundamental physiological processes,
such as cell proliferation, differentiation, metabolism, cell death, and survival [62–64]. Out of
nine genes differentially expressed in our study, five are included in the PI3K-AKT pathway, with
three of them—FN1, NGFR, and THBS1—being associated with tumor progression [65–68]. Besides,
upregulated ANGPT1 and downregulated COl11A1 are related to a better prognosis in lung cancer
metastasis and proliferation in colorectal cancer [68,69]. Another gene, TNFSF10, was identified as
upregulated in U251MTAP−/−. This gene is frequently associated with the pro-apoptotic process by
caspase 8 activation [70,71]. Curiously, only two genes, GPC4 and IL13RA2, showed altered expression
for SW1088MTAP+/+ cell line when compared to the control. These two genes exhibit differential
expression and controversial function in various tumors acting as tumor promoters and inhibitors in a
cancer type-specific manner [72–75].
Importantly, in U251MTAP−/− and SW1088MTAP+/+ edited glioma cells, we showed that
MTAP does not regulate glioma cell proliferation, migration, and invasion mechanisms, major cancer
biological features of classic tumor suppressor genes. The results are consistent with the ones observed
in our mRNA expression analysis obtained by the Pan-Cancer Pathway Panel assay. For these genes,
significant differences were observed only for FN1 and MAPK10 between U251MTAP−/− and U251EV
without difference for other genes evaluated. A recent study with prostate cancer cells silenced for
MTAP also showed similar growth rates to controls [33]. Furthermore, it was observed in hepatocellular
carcinoma that the re-expression of MTAP did not change the proliferation rates when compared to
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mock controls [28]. In gliomas, a recent study showed compelling data that MTAP loss is responsible
for epigenetic remodeling and stemness properties [40]. The comparison of the present study with
Hansen et al. [40] shows an important limitation related to culture systems. Our findings were obtained
from 2D monolayer cultures, a high-serum adherent culture system that failed to maintain glioma
stem-like subpopulation of cells and overrepresented only neoplastic cells [76]. We highlight that
the process of in vitro culturing of GBM cells is fraught with challenges [77]. Although Hansen and
colleagues provided the first evidence for relevance of MTAP loss in stemness-induction in GBM, their
study also failed to account for a wide range of factors known to influence tumor growth, migration,
invasion, and resistance to therapy. Therefore, for now, despite efforts, there is a lack of satisfactory
methods for detailed monitoring of molecular and cellular determinants of tumor growth in patients
as well as ideal in vitro systems for modeling of these processes [77]. Thus, additional studies with
implementation of new culture models that better recapitulate the complex reality of glioma growing
in situ are warranted to address this topic.
MTAP has been reported as an important therapeutic regulator. It may contribute to selective
therapy with thiopurines in combination with MTA in MTAP-deleted tumors as a strategy to induce
selective cell death [19,40,78]. However, in the context of treatment strategy, MTAP status as a factor of
molecular vulnerability to increase the efficacy of treatment in patients with glioma should be further
studied with caution. Our data provide arguments towards the lack of strong biological importance of
MTAP in gliomagenesis. Clearly, a better understanding of the molecular changes of MTAP-depleted
cells is needed to exploit this direct and indirect molecular vulnerability, increasing the efficacy of
treatment in patients with glioma.
In summary, the present work showed that loss of MTAP expression is a frequent event in
high-grade gliomas. In silico and in vitro models provided evidences towards the lack of strong
biological importance of MTAP in gliomas. This study also showed that, despite the frequent loss of
MTAP, it does not have a clinical impact in survival and does not act as a canonic tumor suppressor
gene in gliomas.
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Appendix A
Appendix A.1. Cell Lines
One cell line derived from normal astrocytes (NHA), seven primary glioma cell lines, and 11 human
glioma cell lines were evaluated. Human glioma cell lines were as follows: U251 (obtained from
Costello Laboratory), GAMG (obtained from DSMZ, German Collection of Microorganisms and Cell
Cultures), RES259, SF188, UW479, and KNS42 (obtained from Bax et al. [79] ), A172, U87MG, SW1088,
SW1783, and T98G (obtained from ATCC, American Type Culture Collection), NHA (obtained from The
European Collection of Authenticated Cell Cultures (ECACC). NHA, pediatric, and adult glioma cell
lines (RES259, SF188, UW479, KNS42, U251, GAMG, A172, U87MG, SW1088, SW1783, and T98G) were
grown in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO®, Paisley, Scotland, UK). Cell culture
media were supplemented with 10% fetal bovine serum (FBS) (GIBCO®, Paisley, Scotland, UK) and 1%
penicillin-streptomycin (P/S) (GIBCO®, Paisley, Scotland, UK). Primary short-term and immortalized
glioma cell lines (HCB27, HCB28, HCB18, HCB149, HCB29, HCB2, and HCB151) established at Hospital
de Cancer de Barretos, Brazil [80,81] were cultured in DMEM medium supplemented with 10% FBS
and 1% P/S. All cell lines were checked for the absence of mycoplasma infection. Authentication of
cell lines was performed and confirmed by short tandem repeat (STR) DNA typing according to the
International Reference Standard for Authentication of Human Cell Lines.
Appendix A.2. Gene Editing
Appendix A.2.1. CRISPR/Cas9-Mediated MTAP Gene Editing
The U251 cell line was transfected with CRISPR/Cas9 KO (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) according to the modified supplier’s protocol. Briefly, in a six-well tissue culture plate, 2.5 x
105 cells were seeded in 1 mL of DMEM medium supplemented with FBS at 10% per well, at 37 ◦C and
supplemented with 5% CO2 per 24 h until reaching 70–90% of confluence. Next, DMEM medium was
removed, and 200 µL of opti-MEM was added into wells and cultivated at 37 ◦C and 5% of CO2 until
the transfection solutions were ready. For solution A, 1.5 µg of MTAP CRISPR/Cas9 KO plasmid (h)
(sc-406223) and 1.5 µg of MTAP HDR Plasmid (h) (sc-406223-HDR) or 3.0 µg of Control CRISPR/Cas9
Plasmid (sc-418922) were added into opti-MEM medium to bring the final volume to 150 uL. For
solution B, 15 uL of UltraCruz Transfection Reagent (sc-395739) was added into the opti-MEM medium
to a total of 150 µL. The Plasmid DNA solution (Solution A) was then added dropwise directly to the
UltraCruz Transfection Reagent (Solution B), vortexed, and incubated for 20 min at room temperature
(Solution C). Then, 300 µL of solution C was added into each well and incubated for 72 h under
conditions normally used to culture the cells. At 72 h post-transfection, the medium was aspirated,
and DMEM medium containing 10% of FSB and 5 µg/mL of puromycin antibiotic was added (Santa
Cruz, Dallas, USA #CAS 58-58-2) for 7 days. Every 3 days, the medium was aspirated, and new freshly
selective media were added into well. The success of MTAP CRISPR/Cas9 KO Plasmid and HDR
Plasmid was confirmed by the detection of the red fluorescent protein (RFP) via fluorescent microscopy
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and Western blotting assay. The stably deleted cell line was designated as U251 MTAP−/− and U251
EV for empty vector control as well as the wild type parental control (U251 WT).
Appendix A.2.2. Cell Transduction and Generation of MTAP Overexpressing Cell Line
The lentivirus for MTAP overexpression (MTAP Lentivirus Human, No. #LVP712487) and the
control lentivirus (pLenti-III-CMV-GFP-2A-Puro-Blank Control Lentiviral Vector, No. #LV590) were
obtained commercially from Applied Biological Materials (ABM Inc.®, Richmond, BC, Canada). Stable
cell lines were generated by transducing the MTAP or the Blank control (without insert) and were
selected with 25 µg/mL puromycin according to the supplier’s protocol. First, to select the multiplicity
of infection (MOI), the green fluorescent protein (GFP) control (LV006) was transfected into the SW1088
cell line cultured in a 96-well tissue culture plate (TPP®, Lausanne, Vaud, Switzerland) at a MOI of 2,
4, 6, 8, or 10. The success of GFP expression was observed under a fluorescence microscope (Leica,
Wetzlar, Hesse, Germany) after 48 h. An MOI=10 was selected for subsequent experiments, which
was adequate for sufficient genetic overexpression in the infected cells with minimum damage. After
that, 1 × 104 cells (SW1088) were seeded in a 96-well tissue culture plate in 100 µL of DMEM medium
supplemented with FBS at 10% per well at 37 ◦C and supplemented with 5% CO2 overnight until
reaching 70–80% of confluence. Next, the DMEM medium was removed from wells and replaced with
150 µL of transduction mixture [Viral Plus transduction enhancer (G968) diluted 1:100 into MTAP
Lentiviral vector, #LVP712487 or Puro-Blank Lentivirus; #LV590; ABM Inc.®, Richmond, BC, Canada]
following incubation of the 96-plate at 37 ◦C with 5% CO2 overnight. After 72 h, the DMEM medium
was removed and replaced with 100 µL of complete medium. Stably transfected cells were selected by
the addition of 25 µg/mL puromycin to the medium, which was changed every 3 days. The selection
was terminated after 7 days when the uninfected control cells were completely dead. The stably
expressing cell lines were designated as SW1088 MTAP+/+ and SW1088 LB for lentivirus blank control,
beyond the wild type cell line (SW1088 WT). The infected cells were selected using puromycin antibiotic
(25 µg/mL) for 10 days, and stable expression was confirmed by Western blot.
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